Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06258642
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-14
First Post:
2024-02-06
Brief Title:
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
Study of Irinotecan Liposome Combined With Anlotinib as Second-line Regimen in Patients With Small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single arm multi-center prospective clinical trial The purpose of this study is to evaluate the efficacy and safety of liposomal irinotecan combined with anlotinib hydrochloride for relapsed small-cell lung cancer who have progressed on or less than 6 month after platinum-based first-line therapy
Detailed Description:
Patients will receive irinotecan liposome injection at 70 mgm2 intravenously on Days 1 of every 14-day cycle and anlotinib 12 mgday for 2 consecutive weeks and then discontinued for 1 week The treatment is continued until disease progression or intolerable toxicity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None